Browse HLA-B

Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF07654 Immunoglobulin C1-set domain
PF00129 Class I Histocompatibility antigen
PF06623 MHC_I C-terminus
Function

Involved in the presentation of foreign antigens to the immune system.

> Gene Ontology
 
Biological Process GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002479 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent
GO:0002480 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0034340 response to type I interferon
GO:0034341 response to interferon-gamma
GO:0042590 antigen processing and presentation of exogenous peptide antigen via MHC class I
GO:0048002 antigen processing and presentation of peptide antigen
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060337 type I interferon signaling pathway
GO:0071346 cellular response to interferon-gamma
GO:0071357 cellular response to type I interferon
Molecular Function GO:0003823 antigen binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042605 peptide antigen binding
Cellular Component GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0012507 ER to Golgi transport vesicle membrane
GO:0030133 transport vesicle
GO:0030134 ER to Golgi transport vesicle
GO:0030135 coated vesicle
GO:0030139 endocytic vesicle
GO:0030176 integral component of endoplasmic reticulum membrane
GO:0030658 transport vesicle membrane
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030670 phagocytic vesicle membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
GO:0031901 early endosome membrane
GO:0042611 MHC protein complex
GO:0042612 MHC class I protein complex
GO:0044440 endosomal part
GO:0045335 phagocytic vesicle
GO:0071556 integral component of lumenal side of endoplasmic reticulum membrane
GO:0098552 side of membrane
GO:0098553 lumenal side of endoplasmic reticulum membrane
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
hsa04145 Phagosome
hsa04514 Cell adhesion molecules (CAMs)
hsa04612 Antigen processing and presentation
hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983170: Antigen Presentation
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-1236974: ER-Phagosome pathway
R-HSA-1236977: Endosomal/Vacuolar pathway
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HLA-B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between HLA-B and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25972070Head and Neck Squamous Cell CarcinomaPromote immunityEGFR induces HLA downregulation through SHP-2/STAT1 suppression. Abrogating EGFR-induced immune escape mechanisms and restoring STAT1 signaling to reverse HLA downregulation using cetuximab should be combined with strategies to enhance adaptive cellular immunity.
25294906Thyroid Gland Papillary CarcinomaPromote immunity (infiltration)Both MHC class I and β2-microglobulin expression was reduced or absent in 76% of PTC specimens and was associated with reduced tumor-infiltrating immune cells, including effector (CD3(+), CD8(+), CD16(+)) and suppressor (FoxP3(+)) populations.
21908738MyelomaPromote immunityMHC class I expression on myeloma cells and contact with T cells were required for CD8(+) T cell divisions and DP-T cell development. DP-T cells present in myeloma-infiltrated bones contained a higher proportion of cells expressing cytotoxic mediators IFN-gamma and/or perforin compared with single-positive CD8(+) T cells, acquired the capacity to degranulate as measured by CD107 expression, and contributed to an elevated perforin level seen in the myeloma-infiltrated bones.
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HLA-B in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HLA-B in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.7240.244
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6890.832
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.7740.405
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2910.538
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0180.995
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6410.868
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4150.568
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9520.734
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2470.939
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4550.7
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9630.871
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.240.109
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HLA-B in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HLA-B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HLA-B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HLA-B.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HLA-B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HLA-B expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HLA-B and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHLA-B
Namemajor histocompatibility complex, class I, B
Aliases ankylosing spondylitis; HLAB; SPDA1; HLA class I histocompatibility antigen, B alpha chain; MHC Class I HLA ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HLA-B collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.